Literature DB >> 17038465

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

D E Furst1, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, M H Weisman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17038465      PMCID： PMC1798383          DOI： 10.1136/ard.2006.061937

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  208 in total

1.  Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

Authors:  Leen De Rycke; Elli Kruithof; Nancy Van Damme; Ilse E A Hoffman; Nancy Van den Bossche; Filip Van den Bosch; Eric M Veys; Filip De Keyser
Journal:  Arthritis Rheum       Date:  2003-04

2.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial.

Authors:  U Chaudhari; P Romano; L D Mulcahy; L T Dooley; D G Baker; A B Gottlieb
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

3.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

4.  Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.

Authors:  Y Allanore; J Sellam; F Batteux; C Job Deslandre; B Weill; A Kahan
Journal:  Clin Exp Rheumatol       Date:  2004 Nov-Dec       Impact factor: 4.473

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

7.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

8.  Infliximab as a novel therapy for refractory Kawasaki disease.

Authors:  Jennifer E Weiss; B Anne Eberhard; Devyani Chowdhury; Beth S Gottlieb
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

9.  Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

Review 10.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103
View more
  20 in total

1.  ELISPOT-IFN-gamma assay instead of tuberculin skin test for detecting latent Mycobacterium tuberculosis infection in rheumatic patients candidate to anti-TNF-alpha treatment.

Authors:  Stefania Girlanda; Paola Mantegani; Elena Baldissera; Patrizia Aiello; Manuela Ratti; Maria Grazia Sabbadini; Claudio Fortis
Journal:  Clin Rheumatol       Date:  2010-07-20       Impact factor: 2.980

Review 2.  Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?

Authors:  Theodoros Kelesidis; Amandeep Salhotra; Jorge Fleisher; Daniel Z Uslan
Journal:  J Infect       Date:  2010-02-20       Impact factor: 6.072

Review 3.  TNFalpha blockade in human diseases: an overview of efficacy and safety.

Authors:  Jan Lin; David Ziring; Sheetal Desai; Sungjin Kim; Maida Wong; Yael Korin; Jonathan Braun; Elaine Reed; David Gjertson; Ram Raj Singh
Journal:  Clin Immunol       Date:  2007-10-04       Impact factor: 3.969

Review 4.  Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.

Authors:  Shi Wei; Gene P Siegal
Journal:  Pathol Res Pract       Date:  2008-08-30       Impact factor: 3.250

5.  Baseline comorbidities in a population-based cohort of rheumatoid arthritis patients receiving biological therapy: data from the Australian rheumatology association database.

Authors:  Andrew M Briggs; Lyn March; Marissa Lassere; Christopher Reid; Lyndall Henderson; Bridie Murphy; Rosemarie van den Haak; Adam Rischin; Margaret Staples; Rachelle Buchbinder
Journal:  Int J Rheumatol       Date:  2009-09-01

6.  Prevalence of positive ppd in a cohort of rheumatoid arthritis patients.

Authors:  Maria Natalia Tamborenea; Guillermo Tate; Eduardo Mysler; Jose Debonis; Adrian Schijedman
Journal:  Rheumatol Int       Date:  2009-07-04       Impact factor: 2.631

7.  Protein biochip array technology to monitor rituximab in rheumatoid arthritis.

Authors:  S Fabre; C Guisset; L Tatem; N Dossat; A M Dupuy; J D Cohen; J P Cristol; J P Daures; C Jorgensen
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

Review 8.  Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.

Authors:  K Visser; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103

9.  Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.

Authors:  B Combe; C Codreanu; U Fiocco; M Gaubitz; P P Geusens; T K Kvien; K Pavelka; P N Sambrook; J S Smolen; R Khandker; A Singh; J Wajdula; S Fatenejad
Journal:  Ann Rheum Dis       Date:  2008-09-15       Impact factor: 19.103

10.  The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project.

Authors:  Burkhard F Leeb; Elke Böttcher; Hans-Peter Brezinschek; Christoph Czerwenka; Manfred Herold; Hans Hitzelhammer; Franz Mayrhofer; Rudolf Puchner; Franz Rainer; Bernhard Rintelen; Michael Schirmer; Ulrike Stuby; Hans Bröll
Journal:  Clin Rheumatol       Date:  2009-11-11       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.